TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28065188
Drug: Flavanone-rich orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanone-rich orange juice (272.1 mg)
Study: 28065188
Drug: Homogenised whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homogenised whole orange (452.8 mg)
Study: 28065188
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (128.9 mg)
Study: 28065188
Drug: Isoenergetic control
Normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic control (0 mg flavanones)
Study: 25327311
Drug: Mitiglinide 10
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 10 mg three times a day
Study: 25327311
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg once a day
Study: 19931080
Drug: DRP/20EE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRP/20EE plus metformin (1,500 mg/d)
Study: 19931080
Drug: DRP/20EE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRP/20EE plus CPA (12.5 mg/d, 10 days per cycle)
Study: 12401731
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg b.i.d. orally)
Study: 10216887
Drug: Docetaxel (Taxotere®)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere®) as second-line chemotherapy
Study: 7565904
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K administration (group A)
Study: 7565904
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin K administration (group B)
Study: 7565904
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin K administration (group C)
Study: 1980827
Drug: molindone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: molindone at pre-established doses equivalent to pre-study neuroleptic
Study: 1980827
Drug: haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: haloperidol at pre-established doses equivalent to pre-study neuroleptic
Study: 1980827
Drug: molindone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: molindone at 200% of pre-study dose
Study: 1980827
Drug: haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: haloperidol at 200% of pre-study dose
Study: 31532802
Drug: Therapist-guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-based cognitive behavioral therapy (ICBT) for 14 weeks
Study: 29273027
Drug: Citrus bergamia
Normalized name: CITRUS BERGAMIA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus bergamia extracts-based formulation (CitriCholess)
Study: 26281160
Drug: Liquid probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid probiotic form based on Enterococcus faecium L3, daily dose of 1.5 x 10(9) CFU for three months
Study: 19448381
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg twice a day with 20 mg esomeprazole once a day
Study: 19448381
Drug: Ibuprofen in
Normalized name: ibuprofen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen in ApoE epsilon4 carriers (n=27)
Study: 11585018
Drug: Mifepristone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (single dose) in early luteal phase
Study: 11585018
Drug: Mifepristone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (single dose) in mid-luteal phase
Study: 11585018
Drug: Mifepristone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone alone or in combination with a prostaglandin
Study: 11585018
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg vs 10 mg)
Study: 489921
Drug: Cimetidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 0.75 mg/kg bw
Study: 489921
Drug: Cimetidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1.5 mg/kg bw
Study: 489921
Drug: Cimetidine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 3.0 mg/kg bw
Study: 489921
Drug: Cimetidine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 6.0 mg/kg bw
Study: 31306331
Drug: Testing or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing or treatment for sexually transmitted infections
Study: 28090798
Drug: GTR 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTR 20 mg/mL daily
Study: 20945090
Drug: Sequential decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential decision-making process regarding adjuvant therapy options (one at a time)
Study: 20945090
Drug: Sequential decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential decision-making process among higher-numeracy participants
Study: 20945090
Drug: Sequential decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential decision-making process among lower-numeracy participants
Study: 15323064
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg/day
Study: 19756164
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/day plus HCTZ 12.5 mg/day
Study: 19756164
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/day (open-label)
Study: 10826311
Drug: Endocrine agents
Normalized name: ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine agents (antiestrogens, progestational drugs, aromatase inhibitors)
Study: 6502506
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (10 mg) administered intravenously
Study: 6502506
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg po four times a day)
Study: 3943267
Drug: Metoprolol (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (12.5, 25, 50, 100 mg)
Study: 3943267
Drug: Bevantolol (18.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol (18.75, 37.5, 75, 150 mg)
Study: 3943267
Drug: Control observations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control observations (no drug)
Study: 29762276
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU injection of Botulinum toxin A (BoNT‐A)
Study: 16343234
Drug: TEC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 with epirubicin 75 mg/m(2))
Study: 16343234
Drug: TC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 without epirubicin)
Study: 11195269
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors (SSRIs) with daily or intermittent dosing
Study: 11195269
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase only SSRI administration
Study: 2064730
Drug: l-dopa (300-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-dopa (300-1000 mg per day) with peripheral decarboxylase inhibitor (benserazide, carbidopa)
Study: 6199470
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intrathecal methotrexate without irradiation (IVIT group)
Study: 15665012
Drug: Asoprisnil 10
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 10 mg QD or higher
Study: 12164298
Drug: Dipstick assay
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dipstick assay for detection of Salmonella typhi-specific IgM antibodies
Study: 10564562
Drug: Becaplermin gel-100
Normalized name: becaplermin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Becaplermin gel-100 microg/g
Study: 8728346
Drug: Doxazosin 1
Normalized name: doxazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (morning administration)
Study: 8728346
Drug: Doxazosin 1
Normalized name: doxazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (evening administration)
Study: 8728346
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of morning and evening administration of doxazosin
Study: 1996576
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD, 0.6 mg/kg/d)
Study: 1996576
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NPD, 1.3 mg/kg/d)
Study: 30664303
Drug: Topiramate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300 mg/day, titrated over 6 weeks and maintained for 6 weeks)
Study: 29298017
Drug: Local collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local collagen treatment
Study: 18317742
Drug: Glutamate injection
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injection (0.1 ml, 0.5 M) into latent MTrPs
Study: 18317742
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection (0.1 ml, 0.9%) into latent MTrPs
Study: 18317742
Drug: Glutamate injection
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injection into non-MTrPs
Study: 18317742
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection into non-MTrPs
Study: 18317742
Drug: Glutamate injection
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injection compared to isotonic saline
Study: 10202876
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (oral E2, 1 mg daily for 12 months, then 2 mg daily) with 5 or 10 mg of dydrogesterone
Study: 7607192
Drug: Naloxone (N;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (N; 1.2 mmol.l‐1; 3 ml)
Study: 7607192
Drug: Placebo (P;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P; 0.9% saline; 3 ml)
Study: 393356
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg intravenous infusion over 30 minutes)
Study: 393356
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg orally thrice daily for six days)
Study: 31843374
Drug: Prescription requirement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription requirement for naloxone
Study: 31843374
Drug: Average price
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average price of naloxone nasal spray
Study: 11587994
Drug: Active smoke
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active smoke inhalation
Study: 9403257
Drug: Povidone-iodine rinsing
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine rinsing 4 times daily
Study: 7520905
Drug: Risperidone at
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone at doses of 6, 10, and 16 mg/day
Study: 7520905
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at a dose of 20 mg/day
Study: 21848706
Drug: Roflumilast, 500
Normalized name: Roflumilast, 500 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast, 500 µg once daily
Study: 20141008
Drug: Emoxypin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxypin (150 mg)
Study: 17270317
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (7.2 g/day for 14 days)
Study: 17270317
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (7.2 g/day for 14 days) in fasting conditions
Study: 11231986
Drug: L-thyroxine [64
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine [64 nmol.day(‐)(1) (0.05 mg.day(‐)(1))]
Study: 11231986
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L-thyroxine and placebo)
Study: 23520976
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg/mL, 0.5 mL)
Study: 23520976
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic saline, 9 mg/mL, 0.5 mL)
Study: 20535948
Drug: Bevacizumab (antiangiogenesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (antiangiogenesis therapy)
Study: 20535948
Drug: Small molecules
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small molecules of VEGF-TKI
Study: 8267489
Drug: Anti-factor Xa
Normalized name: Innohep, 20,000 anti-Factor Xa intl units/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-factor Xa monitoring (targeted range, 0.35 to 0.67 U/mL)
Study: 3114564
Drug: Histamine (0.06‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.06‐2 micrograms in 0.1 ml saline)
Study: 3114564
Drug: Terfenadine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (20, 40, 60, and 120 mg, p.o.)
Study: 20627451
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity behavioral treatment (average 6.5h per week)
Study: 16409338
Drug: IMPACT service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPACT service (Inpatient Management of acute Pain and Advice on Clinical Treatment)
Study: 10987602
Drug: Azimilide 100
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 100 mg and 125 mg
Study: 10987602
Drug: Azimilide 50
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 50 mg
Study: 14967728
Drug: Azimilide 100
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 100 mg
Study: 3085131
Drug: Mecamylamine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (2.5, 5.0, 10, 20 mg)
Study: 26701793
Drug: MFGM (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM (10 g Lacprodan PL-20, twice daily)
Study: 26701793
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 g Miprodan 30, twice daily)
Study: 12182742
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple therapy
Study: 7669310
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with alfentanil (0.5 mcg/kg initial dose, continuous infusion 0.2 to 0.5 mcg/kg/min, self-administered 3 to 5 mcg/kg with a 5-minute lockout)
Study: 7669310
Drug: Physician-controlled analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-controlled analgesia with continuous infusions (0.75 mcg/kg/min) and intermittent boluses (5 mcg/kg) of alfentanil
Study: 1836062
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet (0.15 g EPA/d, 0.41 g DHA/d)
Study: 1836062
Drug: Fish +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish + Oil diet (0.99 g EPA/d, 0.99 g DHA/d)
Study: 1836062
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil alone (5 g/d for 6 weeks, 0.84 g EPA/d, 0.48 g DHA/d)
Study: 31603245
Drug: 3-month strict
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month strict oral hygiene phase
Study: 31603245
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no instructions or motivation on oral hygiene)
Study: 7994666
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240 mg (oral administration)
Study: 2563744
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 8.8 mg azelastine
Study: 197446
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (15 to 60 mg, subcutaneously administered)
Study: 31565898
Drug: NA-XY (nalbuphine-xylazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-XY (nalbuphine-xylazine combination: xylazine 1.1mL/100 kg IV and nalbuphine 1 mg/kg IV)
Study: 29164254
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (7.5 mg/d)
Study: 23314000
Drug: Routine Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Family Therapy (RFT)
Study: 23644823
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) - up to 1500 mg iron
Study: 12826316
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin (GP) - gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 2.
Study: 12826316
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus carboplatin (GC) - gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin AUC=5 on day 2.
Study: 9124195
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate 200 mg/m2/day and hydroxyurea 500 mg/day
Study: 9124195
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate 250 mg/m2/day and hydroxyurea 1,000 mg/day
Study: 9124195
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate 300 mg/m2/day and hydroxyurea 1,000 mg/day
Study: 9124195
Drug: Gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gallium nitrate 350 mg/m2/day and hydroxyurea 1,000 mg/day
Study: 9124195
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gallium nitrate and hydroxyurea
Study: 2940475
Drug: Transdihydrolisuride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdihydrolisuride (1 mg daily)
Study: 8964274
Drug: Felbamate monotherapy
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate monotherapy
Study: 6614410
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg cimetidine orally 120 to 180 minutes prior to induction of anaesthesia
Study: 6614410
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg cimetidine rectally in small children up to 15 kg
Study: 21157170
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no moxibustion treatment)
Study: 16386621
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir for the first 21 days
Study: 16386621
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir followed by oral ganciclovir up to day 120 posttransplantation (historical control group)
Study: 10348929
Drug: Highly selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly selective inhibitors of cyclooxygenase-2 (COX-2)
Study: 2279802
Drug: Ibuprofen (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (7 mg/kg)
Study: 2279802
Drug: Paracetamol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (8 mg/kg)
Study: 7247696
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg i.v. infusion)
Study: 7247696
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal volume and infusion speed)
Study: 31491873
Drug: Phytosterol emulsion
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol emulsion (1.5 g/day phytosterol equivalents)
Study: 22326642
Drug: HBV-ISS (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV-ISS (2 doses at 0 and 4 weeks)
Study: 22326642
Drug: HBV-Eng (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV-Eng (3 doses at 0, 4, and 24 weeks)
Study: 19497643
Drug: Educational magazine
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational magazine (twice monthly)
Study: 8064171
Drug: Garlic preparation
Normalized name: garlic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic preparation (Kwai)
Study: 3120557
Drug: Terfenadine associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine associated with cytoprotective drugs (pirenzepine or rosaprostol)
Study: 3120557
Drug: Terfenadine associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine associated with anti-H2 receptor antagonists (ranitidine or famotidine)
Study: 18349597
Drug: Mesotherapy (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesotherapy (mixed solution of aminophylline, buflomedil, and lidocaine) injected weekly into the superficial dermis of one thigh for 12 weeks.
Study: 18349597
Drug: Mesotherapy (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesotherapy (mixed solution of aminophylline, buflomedil, and lidocaine)